The latter, denoted 68Ga-PSMA (Figure 6C), has had a big impact in clinical trials showing high specificity, usefulness in recurrent cases and successful localisation of metastases and is en route of becoming a standard in prostate cancer management in the clinic (Cortezon-Tamarit et al., 2019). This evidence concerns the gene FOLH1 and prostate carcinoma.